Tagrisso adjuvant trial overwhelmingly positive
This announcement contains inside information 10 April 2020 18:00 BST Tagrisso Phase III ADAURA trial will be unblinded early after overwhelming efficacy in the adjuvant treatment of patients with EGFR-mutated lung cancer ADAURA is the first global trial for an EGFR inhibitor to show statisticallysignificant and clinically meaningful benefit in adjuvant treatment of lung cancer Plans for regulatory submission already underway The ADAURA Phase III trial for Tagrisso (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth